Bivalirudin Dosing for HIT with Normal Renal and Hepatic Function
For medical treatment of HIT in an adult with normal renal and hepatic function, initiate bivalirudin as a continuous IV infusion at 0.15-0.25 mg/kg/hour without a bolus, and titrate to maintain aPTT at 1.5-2.5 times control. 1
Context-Specific Dosing
The dosing of bivalirudin varies significantly based on clinical context:
Medical Management of HIT (Non-Procedural)
- Initial dose: 0.15-0.25 mg/kg/hour IV infusion
- No bolus required for medical management
- Target: aPTT 1.5-2.5 times baseline
- Note: Evidence for this indication is limited, but this represents the most recent guideline recommendation 1
Percutaneous Coronary Intervention (PCI)
- Bolus: 0.75 mg/kg IV
- Infusion: 1.75 mg/kg/hour during procedure
- Continue up to 4 hours post-procedure (especially in STEMI)
- Monitoring: If ACT <225 seconds after bolus, increase infusion by 0.25 mg/kg/hour 1, 2
Cardiac Surgery
- Without CPB: 0.75 mg/kg bolus + 1.75 mg/kg/hour infusion; target ACT >300 seconds
- With CPB: 1 mg/kg bolus + 50 mg in pump priming + 2.5 mg/kg/hour infusion; target ACT >2.5 times baseline 1
Critical Monitoring Parameters
Monitor aPTT closely during the first 24 hours, as time to therapeutic range averages 5-11 hours but can extend to 30+ hours in some patients 3, 4. The 2020 French guidelines emphasize that bivalirudin is a priority agent for severe HIT requiring short half-life anticoagulation with strict biological monitoring 1.
Dose Titration Strategy
- Measure aPTT 2-4 hours after initiation or dose change
- Adjust in increments of 0.005-0.01 mg/kg/hour based on aPTT response
- Expect 53-58% of aPTT values to fall within target range during steady-state therapy 4, 5
Important Caveats
Bivalirudin is contraindicated in severe renal failure (CrCl <30 mL/min) 1. While the FDA label states this as a contraindication 2, the 2020 guidelines explicitly note that in severe renal impairment, only argatroban should be used 1.
Renal Dosing Adjustments (if CrCl 30-60 mL/min for PCI only)
The FDA label recommends reducing the infusion to 1.4 mg/kg/hour for moderate renal impairment during PCI 2. However, for medical management of HIT, bivalirudin should be avoided entirely in severe renal dysfunction and argatroban used instead 1.
Hepatic Considerations
Bivalirudin is safe in severe hepatic impairment (Child-Pugh C), unlike argatroban which is contraindicated 1. This makes bivalirudin the preferred direct thrombin inhibitor when both HIT and severe liver disease coexist.
Practical Considerations
The anticoagulant effect of bivalirudin subsides approximately 1 hour after discontinuation due to its 25-minute half-life 2. This short duration of action provides both a safety advantage in bleeding situations and necessitates continuous infusion without interruption.
Resistance to bivalirudin is rare but documented, with some patients requiring doses up to 1.8 mg/kg/hour to maintain therapeutic aPTT 6. If therapeutic targets are not achieved with standard dosing after appropriate titration time, consider measuring bivalirudin levels if available, though this is not routinely necessary 1.
Drug Compatibility
Do not administer alteplase, amiodarone, amphotericin B, chlorpromazine, diazepam, dobutamine, prochlorperazine, reteplase, streptokinase, or vancomycin in the same IV line as bivalirudin 2.
Guideline Hierarchy
The 2020 French Anaesthesia guidelines [1-1] provide the most detailed and recent recommendations for bivalirudin dosing in HIT, superseding the 2012 ACCP guidelines 7 which suggested bivalirudin primarily for PCI contexts. The FDA label 2 officially approves bivalirudin only for PCI in HIT patients, but off-label use for medical management is well-established in current practice with the dosing parameters outlined above.